MRI影像组学分析预测鼻咽癌患者诱导化疗反应
回顾性纳入184例鼻咽癌患者(主要队列132例、验证队列52例),基于治疗前增强T1WI和T2WI提取影像组学特征建模,其中CE-T1+T2WI影像组学标签在主要队列AUC为0.940、验证队列AUC为0.952,结论认为基于MRI的影像组学模型可能有助于接受诱导化疗的鼻咽癌患者的个体化风险分层和治疗。
要点
- CE-T1+T2WI影像组学标签区分诱导化疗反应:主要队列AUC 0.940、验证队列AUC 0.952。
- 该标签主要队列敏感度83.1%、特异度91.8%、准确率87.1%;验证队列敏感度74.2%、特异度95.2%、准确率82.7%。
- 共构建4个模型:CE-T1影像组学标签、T2WI影像组学标签、CE-T1+T2WI影像组学标签及CE-T1影像组学列线图。
核心结论
- 基于MRI的影像组学模型可能有助于接受诱导化疗的鼻咽癌患者的个体化风险分层和治疗。
研究设计与样本
- 回顾性分析纳入184例连续鼻咽癌患者,主要队列132例、验证队列52例,基于治疗前增强T1WI和T2WI提取影像组学特征,经筛选后结合临床特征建模,以AUC、敏感度、特异度和准确率评价模型预测诱导化疗反应的表现。
诊断标准与关键数值
- CE-T1+T2WI影像组学标签区分诱导化疗反应:主要队列AUC 0.940(95%CI 0.885-0.974)、敏感度83.1%、特异度91.8%、准确率87.1%;验证队列AUC 0.952(95%CI 0.855-0.992)、敏感度74.2%、特异度95.2%、准确率82.7%。
临床应用与阅片要点
- 原文结论认为MRI影像组学模型可能有助于鼻咽癌诱导化疗患者的个体化风险分层和治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To establish and validate radiomic models for response prediction to induction chemotherapy (IC) in nasopharyngeal carcinoma (NPC) using the radiomic features from pretreatment MRI.
MATERIALS AND METHODS: This retrospective analysis included 184 consecutive NPC patients, 132 in the primary cohort and 52 in the validation cohort. Radiomic features were derived from contrast-enhanced T1-weighted imaging (CE-T1) and T2-weighted imaging (T2-WI) for each subject. The radiomic features were then selected and combined with clinical characteristics to build radiomic models. The potential of the radiomic models was evaluated based on its discrimination and calibration. To measure the performance of these radiomic models in predicting the treatment response to IC in NPC, the area under the receiver operating characteristic curve (AUC), and sensitivity, specificity, and accuracy were used.
RESULTS: Four radiomic models were constructed in the present study including the radiomic signature of CE-T1, T2-WI, CE-T1 + T2-WI, and the radiomic nomogram of CE-T1. The radiomic signature of CE-T1 + T2-WI performed well in distinguishing response and non-response to IC in patients with NPC, which yielded an AUC of 0.940 (95% CI, 0.885-0.974), sensitivity of 83.1%, specificity of 91.8%, and accuracy of 87.1% in the primary cohort, and AUC of 0.952 (95% CI, 0.855-0.992), sensitivity of 74.2%, specificity of 95.2%, and accuracy of 82.7% in the validation cohort.
CONCLUSION: MRI-based radiomic models could be helpful for personalised risk stratification and treatment in NPC patients receiving IC.
引用
- Wang, Xu, Zhang, et al. Radiomic analysis of MRI for prediction of response to induction chemotherapy in nasopharyngeal carcinoma patients. Clin Radiol. 2023. PMID: 37331848. doi:10.1016/j.crad.2023.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。